Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOLD: Bevacizumab biosimilar + olaparib + durvalumab in relapsed advanced epithelial ovarian cancer
2018-002281-39Phase 2Completed
- Sponsor
- Arcagy-Gineco
- Start
- Jul 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab-equi, olaparib and durvalumab in ovarian cancer, sponsored by Arcagy-Gineco. Primary endpoint: Progression-free survival by irRC. Started Jul 2018; status: completed.
02
Drugs
bevacizumab-equiolaparibdurvalumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2018-002281-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002281-39.